Completed PHASE2 INTERVENTIONAL 1-arm NCT00410605

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Phase II Trial of Bevacizumab Combined With Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapsed or Refractory Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Multiple Myeloma in Relapse Stage II Multiple Myeloma Stage III Multiple Myeloma

Interventions bevacizumab dexamethasone lenalidomide

Updated 7 times since 2017 Last updated: Aug 2, 2017 Started: Nov 30, 2006 Primary completion: Dec 31, 2011 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Myeloma in Relapse and Stage II Multiple Myeloma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Oct 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — Oct 2017 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States
• Pittsburgh, United States